» Articles » PMID: 28276944

Imaging and Spectroscopic Approaches to Probe Brain Energy Metabolism Dysregulation in Neurodegenerative Diseases

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Changes in energy metabolism are generally considered to play an important role in neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's diseases. Whether these changes are causal or simply a part of self-defense mechanisms is a matter of debate. Furthermore, energy defects have often been discussed solely in the context of their probable neuronal origin without considering the cellular heterogeneity of the brain. Recent data point towards the existence of a tri-cellular compartmentation of brain energy metabolism between neurons, astrocytes, and oligodendrocytes, each cell type having a distinctive metabolic profile. Still, the number of methods to follow energy metabolism in patients is extremely limited and existing clinical techniques are blind to most cellular processes. There is a need to better understand how brain energy metabolism is regulated in health and disease through experiments conducted at different scales in animal models to implement new methods in the clinical setting. The purpose of this review is to offer a brief overview of the broad spectrum of methodological approaches that have emerged in recent years to probe energy metabolism in more detail. We conclude that multi-modal neuroimaging is needed to follow non-cell autonomous energy metabolism dysregulation in neurodegenerative diseases.

Citing Articles

Proteome analysis of the prefrontal cortex and the application of machine learning models for the identification of potential biomarkers related to suicide.

Rojo-Romero M, Gutierrez-Najera N, Cruz-Fuentes C, Romero-Pimentel A, Mendoza-Morales R, Garcia-Dolores F Front Psychiatry. 2025; 15:1429953.

PMID: 40051599 PMC: 11882514. DOI: 10.3389/fpsyt.2024.1429953.


Creatine as a Therapeutic Target in Alzheimer's Disease.

Smith A, Morris J, Carbuhn A, Herda T, Keller J, Sullivan D Curr Dev Nutr. 2023; 7(11):102011.

PMID: 37881206 PMC: 10594571. DOI: 10.1016/j.cdnut.2023.102011.


Cell-specific vulnerability to metabolic failure: the crucial role of parvalbumin expressing neurons in creatine transporter deficiency.

Ghirardini E, Sagona G, Marquez-Galera A, Calugi F, Navarron C, Cacciante F Acta Neuropathol Commun. 2023; 11(1):34.

PMID: 36882863 PMC: 9990224. DOI: 10.1186/s40478-023-01533-w.


Metabolic contrast agents produced from transported solid C-glucose hyperpolarized via dynamic nuclear polarization.

Capozzi A, Kilund J, Karlsson M, Patel S, Pinon A, Vibert F Commun Chem. 2023; 4(1):95.

PMID: 36697707 PMC: 9814755. DOI: 10.1038/s42004-021-00536-9.


A genetically modified minipig model for Alzheimer's disease with SORL1 haploinsufficiency.

Andersen O, Bogh N, Landau A, Ploen G, Jensen A, Monti G Cell Rep Med. 2022; 3(9):100740.

PMID: 36099918 PMC: 9512670. DOI: 10.1016/j.xcrm.2022.100740.


References
1.
Howarth C, Gleeson P, Attwell D . Updated energy budgets for neural computation in the neocortex and cerebellum. J Cereb Blood Flow Metab. 2012; 32(7):1222-32. PMC: 3390818. DOI: 10.1038/jcbfm.2012.35. View

2.
De Michele R, Carimi F, Frommer W . Mitochondrial biosensors. Int J Biochem Cell Biol. 2014; 48:39-44. DOI: 10.1016/j.biocel.2013.12.014. View

3.
Damiano M, Galvan L, Deglon N, Brouillet E . Mitochondria in Huntington's disease. Biochim Biophys Acta. 2009; 1802(1):52-61. DOI: 10.1016/j.bbadis.2009.07.012. View

4.
Nasrallah F, Pages G, Kuchel P, Golay X, Chuang K . Imaging brain deoxyglucose uptake and metabolism by glucoCEST MRI. J Cereb Blood Flow Metab. 2013; 33(8):1270-8. PMC: 3734779. DOI: 10.1038/jcbfm.2013.79. View

5.
Chaturvedi R, Beal M . Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol Cell Neurosci. 2012; 55:101-14. DOI: 10.1016/j.mcn.2012.11.011. View